JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit

Key Takeaways J&J reported Q3 EPS of $2.80, up 15.7%, with revenue rising 6.8% to $24 billion.Strong results in Innovative Medicines and MedTech units drove J&J to raise 2025 sales guidance.J&J will spin off its Orthopaedics business, DePuy Synthes, to focus on faster-growing MedTech areas.Johnson & Johnson’s (JNJ) third-quarter 2025 earnings came in at $2.80 per share, which beat the Zacks Consensus Estimate of $2.77. Earnings rose 15.7% from the year-ago period.Adjusted earnings exclude intangible amortiz ...